Overview
CDK4/6 inhibitors combined with endocrine therapy (ET) are the cornerstone of first-line treatment for hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- MBC). Palociclib, the first approved CDK4/6i, has demonstrated—in clinical trials and real-world settings—improved progression-free survival, tumor response, and overall survival when compared with ET alone across diverse HR+/HER2− MBC populations. However, little is known about the effectiveness of CDK4/6i treatments in patients who are overweight or obese, common conditions associated with a higher risk of breast cancer.
Using the Flatiron Health EHR-derived Panoramic database comprised of >940K patients with breast cancer, this study analysed data from over 8,000 patients. The study found improved overall survival for overweight and obese HR+/HER2− MBC treated with Palociclib and an aromatase inhibitor than patients treated with an aromatase inhibitor alone.
Why this matters
This study offers valuable real-world evidence into the effectiveness of Palociclib and endocrine therapy as a standard of care treatment for patients who are overweight or obese. The findings also underscore the value of real-world evidence in guiding treatment strategies and complementing traditional clinical trials. Flatiron’s Panoramic datasets offer a scaled, comprehensive, disease-specific solution to answer questions not previously possible, unlocking critical information to improve care and outcomes for people with cancer.